medigraphic.com
SPANISH

Revista de Hematología

  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2023, Number 1

<< Back Next >>

Rev Hematol Mex 2023; 24 (1)

Blood markers are related to severity and requiring of mechanic ventilation in hospitalized patients due to COVID-19

García-Suárez A, López-Vilchis LE, Solorio-Rivera AH, Rivera-Trujillo A, Carranza-Madrigal J
Full text How to cite this article

Language: Spanish
References: 9
Page: 8-14
PDF size: 366.32 Kb.


Key words:

COVID-19, C-reactive protein, Ferritin, Leukocytes, Invasive mechanical ventilation.

ABSTRACT

Objective: To determine the association between blood markers and severity due to COVID-19.
Materials and Methods: Observational, analytical, case-control, retrospective, cross-sectional study was done with records of hospitalized patients with COVID-19 with positive RT-PCR from January 1st, 2021 to December 31st, 2021. Descriptive and analytical statistics were obtained, measures of central tendency were used and other methods such as Student’s t-test to compare continuous numerical variables and χ2 for categorical variables.
Results: Of 687 files reviewed, most patients were male, with a mean age of 56.4 years; all blood marker variables such as leukocyte alterations, D-dimer, C-reactive protein, ferritin and hemotype were associated with a greater probability of requiring invasive mechanical ventilation and death.
Conclusions: In COVID-19 patients with positive RT-PCR requiring hospitalization for ventilatory support, altered levels of leukocytes, D-dimer, C-reactive protein and serum ferritin are strongly associated with an increased risk of requiring invasive mechanical ventilation and death.


REFERENCES

  1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinicalfeatures of patients infected with 2019 novel coronavirus inWuhan, China. Lancet 2020; 395 (10223): 597-506. https://doi. org/10.1016/S0140- 6736(20)30183-5.

  2. Fehr AR, Perlman S. Coronavirus: An overview of theirreplication and pathogenesis. Methods Mol Biol 2015;1282: 1-23. https://doi.org/10.1007/978-1-4939-2438-7.

  3. Triggle CR, Bansal D, Ding H, Islam MM, Farag E, Hadi HA,Sultan AA. A comprehensive review of viral characteristics,transmission, pathophysiology, immune response, andmanagement of SARS-CoV-2 and COVID-19 as a basis forcontrolling the pandemic. Frontiers Immunol 2021; 12:631139. https://doi.org/10.3389/fimmu.2021.631139.

  4. Gennaro FD, Pizzol D, Marotta C, Antunes M, Racalbuto V,Veronese N, et al. Coronavirus diseases (COVID-19) currentstatus and future perspectives: a narrative review. Int JEnviron Res Public Health 2020; 17 (8): 2690. https://doi.org/10.3390/ ijerph17082690.

  5. Massachusetts General Hospital. 2021 [en línea]. [Fecha deconsulta 10 de abril de 2022]. Accesible en: https://www.massgeneral.org/ assets/MGH/pdf/news/coronavirus/aspectos-hematol%C3%B3gicos-durante-el- COVID-19.pdf.

  6. Thomas T, Stefanoni D, Dzieciatkowska M, Issaian A, et al.Evidence for structural protein damage and membranelipid remodeling in red blood cells from COVID-19 patients.J Proteome Res 2020; 19 (11): 4455-4469. doi: 10.1021/acs.jproteome.0c00606.

  7. Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. JIntensive Care 2020; 8: 36. doi: 10.1186/s40560-020-00453-4.

  8. Price LC, McCabe C, Garfield B, Wort SJ. Thrombosis andCOVID-19 pneumonia: the clot thickens! Eur Respir J 2020;56: 2001608. doi: 10.1183/13993003.01608-2020.

  9. Latz CA, DeCarlo C, Boitano L, Png M, et al. Blood type andoutcomes in patients with COVID‐19. Ann Hematol 2020;99: 2113‐2118. doi: 10.1007/s00277-020-04169-1.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Hematol Mex. 2023;24